Preferred Label : selexipag;

MeSH note : structure in first source;

CISMeF synonym : ACT 293987; NS-304;

MeSH synonym : 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide;

MeSH hyponym : ACT293987; ACT-293987;

Is substance : O;

UNII : 5EXC0E384L;

InChIKey : QXWZQTURMXZVHJ-UHFFFAOYSA-N;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-marr/selexipag
2024
false
false
false
France
French
risk management
Uptravi
medication errors
selexipag
patients guideline
guidelines for drug use
Wrong dose
selexipag

---
http://www.prescrire.org/Fr/3/31/53073/0/NewsDetails.aspx
2017
false
false
false
France
French
french abstract
selexipag
hypertension, pulmonary
pulmonary hypertension, nos
gait, nos
hypertensive disease, nos
acetamides
pyrazines

---
https://www.has-sante.fr/portail/jcms/c_2803897/fr/uptravi
https://www.has-sante.fr/portail/jcms/c_2803897/fr/uptravi-selexipag-antithrombotique
2017
false
false
false
France
French
acetamides
pyrazines
selexipag
selexipag
treatment outcome
hypertension, pulmonary
drug therapy, combination
administration, oral
receptors, prostaglandin
adult
aged
prodrugs
antihypertensive agents
antihypertensive agents
evaluation of the transparency committee
guidelines for drug use
selexipag
acetamides
pyrazines

---
https://www.ema.europa.eu/medicines/human/EPAR/Uptravi
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
acetamides
pyrazines
selexipag
selexipag
drug approval
europe
treatment outcome
hypertension, pulmonary
drug therapy, combination
administration, oral
continuity of patient care
receptors, prostaglandin
product surveillance, postmarketing
adult
aged
drug interactions
pregnancy
breast feeding
prodrugs
drug evaluation, preclinical
antihypertensive agents
antihypertensive agents
selexipag
acetamides
pyrazines

---
Nous contacter.
14/06/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.